Empagliflozin + Matching placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Kidney Disease

Conditions

Chronic Kidney Disease

Trial Timeline

Jan 31, 2019 → Jul 2, 2024

NCT ID

NCT03594110

About Empagliflozin + Matching placebo

Empagliflozin + Matching placebo is a phase 3 stage product being developed by Eli Lilly for Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03594110. Target conditions include Chronic Kidney Disease.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Kidney Disease were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03594110	Phase 3	Completed	Jan 31, 2019	Jul 2, 2024	Chronic Kidney Disease

Competing Products

20 competing products in Chronic Kidney Disease

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	25